Abstract:Objective: To investigate the expression of fibroblast growth factor receptor 2 (FGFR2) in clear cell renal cell carcinoma (ccRCC; or kidney renal clear cell carcinoma, KIRC), to analyze the relationship between the expression of FGFR2 and the clinical pathological features and prognosis of ccRCC, to study the relationship between the expression of FGFR2 and other molecules, and to explore its role in the development of ccRCC. Methods: Gene expressional and clinical information of ccRCC patients were downloaded from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus(GEO) database. Next, the data were transformed and collated. In the study, 104 clinical ccRCC samples and corresponding paracancerous normal tissue samples were collected from Department of Urology, Peking University First Hospital. Immunohistochemistry (IHC) was performed and the staining results were scored, so as to compare the expression of FGFR2 in ccRCC and paracancerous normal tissues. Besides, quantify real-time polymerase chain reaction (qRT-PCR) was used to detect the mRNA expression level of FGFR2 in normal renal epithelial cell lines (293) and ccRCC cell lines (786-O, 769-P, OSRC-2, Caki-1, ACHN, and A498). In addition, the relationship between FGFR2 expression and clinical pathological characteristics (including TNM staging and pathological grading) and survival prognosis in ccRCC patients was further analyzed. Furthermore, the relationship between FGFR2 expression and B cells, T cells, natural killer (NK) cells and neutrophil infiltration in the ccRCC patients was analyzed, and the Biological General Repository for Interactionh Datasets (BioGRID) was used to builds protein-protein interaction (PPI) networks to study molecules that interacted with the FGFR2 protein. Results: In the TCGA database, the expression of FGFR2 was down-regulated in ccRCC tissue samples compared with normal tissue samples, and the expression in the GEO database also showed this differences. Furthermore, FGFR2 expression was downregulated in ccRCC clinical samples and ccRCC cell lines, compared with corresponding paracancerous normal tissue or normal renal epithelial cell lines. In addition, FGFR2 high expression was associated with earlier, lower-level ccRCC and was associated with a better prognosis in the patients with ccRCC. Moreover, FGFR2 expression was not significantly related to B cells, T cells, NK cells and neutrophil infiltration, and the PPI network showed that FGFR2 protein interacted with certain molecules. Conclusion: Our work sheds light on the potential role of FGFR2 in the development of ccRCC, suggesting that FGFR2 may serve as a prognostic marker and potential therapeutic target for patients with ccRCC.

Overexpression of FZD1 is Associated with a Good Prognosis and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.

FDX1 expression predicts favourable prognosis in clear cell renal cell carcinoma identified by bioinformatics and tissue microarray analysis

RCC1 functions as a tumor facilitator in clear cell renal cell carcinoma by dysregulating cell cycle, apoptosis, and EZH2 stability

A Novel DNA Methylation Signature Revealed GDF6 and RCC1 As Potential Prognostic Biomarkers Correlated with Cell Proliferation in Clear Cell Renal Cell Carcinoma

Upregulation of Serine Metabolism Enzyme PSAT1 Predicts Poor Prognosis and Promotes Proliferation, Metastasis and Drug Resistance of Clear Cell Renal Cell Carcinoma.

TKI Resistant-Based Prognostic Immune Related Gene Signature in LUAD, in Which FSCN1 Contributes to Tumor Progression.

Sphingosine Kinase 1 Overexpression Contributes to Sunitinib Resistance in Clear Cell Renal Cell Carcinoma

Low Neighbor of Brca1 Gene Expression Predicts Poor Clinical Outcome and Resistance of Sunitinib in Clear Cell Renal Cell Carcinoma.

Bioinformatic analysis identifying FGF1 gene as a new prognostic indicator in clear cell Renal Cell Carcinoma

[Expression and significance of fibroblast growth factor receptor 2 in clear cell renal cell carcinoma]

MP21-17 SPHINGOSINE KINASE 1 OVEREXPRESSION CONTRIBUTES TO SUNITINIB RESISTANCE IN CLEAR CELL RENAL CELL CARCINOMA

Identification and Validation of Soluble Carrier Family Expression Signature for Predicting Poor Outcome of Renal Cell Carcinoma

ZHX2 Drives Cell Growth and Migration Via Activating MEK/ERK Signal and Induces Sunitinib Resistance by Regulating the Autophagy in Clear Cell Renal Cell Carcinoma

CXCR1 Expression Predicts Benefit from Tyrosine Kinase Inhibitors Therapy in Patients with Metastatic Renal Cell Carcinoma

A Novel Cuproptosis-Related Prognostic Model and the Hub Gene FDX1 Predict the Prognosis and Correlate with Immune Infiltration in Clear Cell Renal Cell Carcinoma

High Expression of Stearoyl-CoA Desaturase 1 Predicts Poor Prognosis in Patients with Clear Cell Renal Cell Carcinoma

ZBP1 as a prognostic biomarker correlated with cell proliferation in clear cell renal cell carcinoma

Cuproptosis-related gene FDX1 expression correlates with the prognosis and tumor immune microenvironment in clear cell renal cell carcinoma

Downregulation of FXYD2 is Associated with Poor Prognosis and Increased Regulatory T Cell Infiltration in Clear Cell Renal Cell Carcinoma.

A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression

Enhanced expression of caveolin-1 possesses diagnostic and prognostic value and promotes cell migration, invasion and sunitinib resistance in the clear cell renal cell carcinoma